Healthcare
Sartorius AG(SARTF)
Live Price
Offline$217.65
+0.00% today
1Y Change
+1.15%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- $15.00B
- Revenue Growth
- +4.6%
- EPS Growth
- +84.4%
- Dividend Yield
- 0.3%
Coverage: 256 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sartorius AG (SARTF) is a Healthcare stock with a market cap of $15.00B and listed on OTC. The stock last traded around $217.65 and up 1.1% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +4.6%, EPS growth of +84.4%, a dividend yield of 0.3%. What stands out right now is revenue +4.6%, EPS +84.4%, free cash flow -62.2% with operating margin 16.5% and ROIC 4.6%. The dividend is present but secondary, with a yield around 0.3%. Valuation already assumes a fairly strong business story at P/E 92.2 and price/sales 4.2. Stock Foundry combines SARTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.6% vs +7.6% peer median
Operating Margin
Below sector median
+16.5% vs +19.4% peer median
P/E
Above sector median
92.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Apr 23, 2026 with an EPS surprise of -6.1% and a revenue surprise of +0.1%.
The operating story is still moving forward
Revenue is running at +4.6% and EPS at +84.4%, with operating margin around 16.5%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 23, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | -6.1% | +0.0% | -6.2% | -10.1% |
2026 Feb 16, 2026 | -3.9% | +0.0% | +0.0% | +0.0% |
2025 Oct 16, 2025 | +0.8% | +0.0% | +0.0% | -0.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SARTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SARTF Max Drawdown
-13.65%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SARTF and SPY.
Company Overview
Sartorius AG
Other OTC
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
- Leadership
- Michael Grosse
- IPO Date
- Sep 22, 2010
- Employees
- 13.6k
- Street Address
- Otto-Brenner-Strasse 20
- Mailing
- Göttingen, 37079
- Region
- Göttingen, DE
- Reporting Currency
- USD
- Investor Line
- 49 551 308 0
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 92.2
- EV/EBITDA
- 18.8
- Price/Sales
- 4.2
- Price/Book
- 5.5
Growth
- Revenue
- +4.6%
- EPS
- +84.4%
- Free Cash Flow
- -62.2%
Profitability
- Gross Margin
- 45.6%
- Operating Margin
- 16.5%
- Net Margin
- 4.6%
- ROE
- 6.0%
- ROIC
- 4.6%
Balance Sheet
- Debt/Equity
- 1.58
- Current Ratio
- 0.91
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.